Back to List View Graph View

Cluster of Differentiation 47 (CD47)

CD47 is a cell-surface protein best known as a key innate immune checkpoint and a prominent “don’t eat me” signal.

Where the papers sit

11 papers from the last 6 months study Cluster of Differentiation 47 (CD47) directly · updated from PubMed 11 Nov 2026

Those 11 are all about one subject.

  • CD47 Biology and Therapeutics

    CD47–SIRPα signaling is examined as a regulator of phagocytosis, inflammation, tumor immunity, and tissue protection. Antibody blockade, including magrolimab with azacitidine, is tested against cancer while studies address hematotoxicity, tumor size, and limited in vivo efficacy. Other work engineers CD47-based EV-liposome delivery or describes endogenous axes such as THBS1-CD47 and BPIFB4-platelet-CD47. The shared focus is CD47 biology and therapeutic leverage, without a single consistent disease or developmental direction.

    11 papers

PARADIGM SHIFT

CD47 blockade is not reliably sufficient to produce antitumor benefit in vivo

The phase III study of magrolimab plus azacitidine in untreated higher-risk myelodysplastic syndromes and the study of Fc-silent CD47 blockade with anti-GD2 in immunocompetent, chemoresistant neuroblastoma both challenge the assumption that interrupting the CD47 “Don’t Eat Me” signal will translate into effective tumor clearance. In myelodysplastic syndromes, adding magrolimab did not improve complete remission over azacitidine alone (21.3% versus 23.6%), while in neuroblastoma, CD47 blockade enhanced anti-GD2-driven phagocytosis in vitro but failed to improve tumor control or survival in two in vivo models, including when added to chemoimmunotherapy 42441929Jul 42945335Oct. Together, these findings shift CD47 blockade from a presumed sufficient macrophage-activating treatment to a context-dependent intervention whose clinical or in vivo efficacy may require additional myeloid-reprogramming or other cooperating mechanisms.

NEW DIRECTION

CD47 is presented as a platelet-mediated regulator of immune resilience and longevity

The LAV-BPIFB4–platelet study in centenarians and longevity-variant carriers assigns CD47 a role outside the set’s predominant tumor-checkpoint and therapeutic-delivery frameworks: LAV-BPIFB4 increases CD47 on reticulated and mature platelets, and platelet CD47 suppresses monocyte activation and inflammatory cytokine production. Rather than functioning mainly as a tumor-cell “Don’t Eat Me” signal to be blocked, CD47 is described here as part of a protective platelet immunomodulatory pathway associated with immune robustness in exceptionally long-lived individuals, opening a direction in which increased CD47 activity supports systemic anti-inflammatory resilience 42345378Jun.

Papers

The 11 papers from the last 6 months that study Cluster of Differentiation 47 (CD47) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

CD47 Biology and Therapeutics (11)
  1. CD47 blockade augments anti-GD2 driven phagocytosis in vitro but fails to improve in vivo efficacy in immunocompetent, chemoresistant neuroblastoma preclinical models. PloS one · 27 Oct 2026 PMID 42945335
  2. Serine protease inhibitor A3 is a soluble SIRPα ligand that suppresses inflammation and antitumor immunity. Nature immunology · 23 Oct 2026 PMID 42918845
  3. Single-Particle Deconvolution of Electroporation Artifacts Guides the Rational Engineering of CD47-EV-Liposome Hybrids for siRNA Delivery. ACS applied materials & interfaces · 14 Oct 2026 PMID 42873218
  4. Tumor size limits macrophage activation and imaging response to CD47 blockade in osteosarcoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 17 Aug 2026 PMID 42607363
  5. A potent anti-CD47 antibody decoupling anti-tumor efficacy from hematotoxicity. International immunopharmacology · 11 Aug 2026 PMID 42580138
  6. Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 13 Jul 2026 PMID 42441929
  7. Axitinib promotes stemness and vasculogenic mimicry in triple-negative breast cancer by disrupting THBS1-CD47 axis-mediated endothelial-tumor cell communication. Apoptosis : an international journal on programmed cell death · 11 Jul 2026 PMID 42435251
  8. The LAV-BPIFB4-Platelet-CD47 Axis: A Novel Mechanism Associated With Immune Resilience in Longevity. Aging cell · 25 Jun 2026 PMID 42345378
  9. Targeting CDK4/6 potentiates the efficacy of anti-CD47 therapy via modulating the suppressive function of tumor-associated macrophages. Apoptosis : an international journal on programmed cell death · 17 Jun 2026 PMID 42307815
  10. Kaempferol functionally reprograms CD47 signaling to promote cytoprotection and attenuate oxeiptosis in severe acute pancreatitis. Phytomedicine : international journal of phytotherapy and phytopharmacology · 25 May 2026 PMID 42184499
  11. Machine learning identifies a NETs-related four-gene diagnostic signature for abdominal aortic aneurysm. Medicine · 23 May 2026 PMID 42175497

By study type

Clinical trials (1)
  1. Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 13 Jul 2026 PMID 42441929
Human data, design not indexed (1)
  1. Machine learning identifies a NETs-related four-gene diagnostic signature for abdominal aortic aneurysm. Medicine · 23 May 2026 PMID 42175497
Preclinical: animal, cell and lab studies (9)
  1. CD47 blockade augments anti-GD2 driven phagocytosis in vitro but fails to improve in vivo efficacy in immunocompetent, chemoresistant neuroblastoma preclinical models. PloS one · 27 Oct 2026 PMID 42945335
  2. Serine protease inhibitor A3 is a soluble SIRPα ligand that suppresses inflammation and antitumor immunity. Nature immunology · 23 Oct 2026 PMID 42918845
  3. Single-Particle Deconvolution of Electroporation Artifacts Guides the Rational Engineering of CD47-EV-Liposome Hybrids for siRNA Delivery. ACS applied materials & interfaces · 14 Oct 2026 PMID 42873218
  4. Tumor size limits macrophage activation and imaging response to CD47 blockade in osteosarcoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 17 Aug 2026 PMID 42607363
  5. A potent anti-CD47 antibody decoupling anti-tumor efficacy from hematotoxicity. International immunopharmacology · 11 Aug 2026 PMID 42580138
  6. Axitinib promotes stemness and vasculogenic mimicry in triple-negative breast cancer by disrupting THBS1-CD47 axis-mediated endothelial-tumor cell communication. Apoptosis : an international journal on programmed cell death · 11 Jul 2026 PMID 42435251
  7. The LAV-BPIFB4-Platelet-CD47 Axis: A Novel Mechanism Associated With Immune Resilience in Longevity. Aging cell · 25 Jun 2026 PMID 42345378
  8. Targeting CDK4/6 potentiates the efficacy of anti-CD47 therapy via modulating the suppressive function of tumor-associated macrophages. Apoptosis : an international journal on programmed cell death · 17 Jun 2026 PMID 42307815
  9. Kaempferol functionally reprograms CD47 signaling to promote cytoprotection and attenuate oxeiptosis in severe acute pancreatitis. Phytomedicine : international journal of phytotherapy and phytopharmacology · 25 May 2026 PMID 42184499